靛玉红甲肟对奈达铂抗人食管癌EC-1细胞的化疗增效作用  

Anti-tumor Effect of Indirubin-3'-monoxime Combined with Nedaplatin on Human Esophageal Cancer Cell Line EC-1

作　　者：陈小兵[1,2] 张军辉[1] 罗素霞[2] 邓文英[2] 索振河[1] 

机构地区：[1]郑州大学第一附属医院,450052 [2]河南省肿瘤医院

出　　处：《肿瘤防治研究》2009年第11期914-916,共3页Cancer Research on Prevention and Treatment

基　　金：河南省医药卫生重大攻关项目;卫生部科研基金资助项目(WKJ2007-2-026)

摘　　要：目的探讨靛玉红甲肟(Indirubin-3′-monoxime,IRO)与奈达铂联合应用对人食管癌细胞株EC-1的影响及其作用机制。方法经不同浓度的IRO和(或)奈达铂处理EC-1细胞后,用MTT法测定细胞增殖抑制效应;流式细胞术观察细胞周期变化;免疫组织化学法观察凋亡相关基因表达变化。结果与IRO或奈达铂单药作用相比,IRO与奈达铂联合应用可显著增强人食管癌细胞增殖抑制作用,联合用药后细胞周期分布发生改变,G0/G1期细胞比例下降,G2/M期细胞比例上升,癌细胞Bcl-2基因表达下降,Bax表达增强。结论IRO与奈达铂联合应用具有协同抗食管癌作用,其机制可能与细胞周期调控及凋亡相关基因表达调控有关。Objective To study the anti-tumor effect of Indirubin-3’-monoxime combined with Nedaplatin（Nap） on the human esophageal cancer cell line EC-1,and to reveal its methanism. Methods Human esophageal cancer line EC-1 was treated in vitroby Indirubin-3’-monoxime with or without Nap in various concertration. The cell growth was evaluated by MTT assay,cell cycle distribution were observed by flow cytometry,and the expression of apoptosis-related genes were analyzed by immunohistochemical staining method. Results Compared with Indirubin-3-’monoxime or Nap individual drug groups,Indirubin-3’-monoxime combined with Nap obviously increased the inhibitory rate of the human esophageal cancer cell line EC-1.In the groups treated by the combinatio of Indirubin-3’-monoxime and Nap, the cell cycle distribution was altered.In this case, the ratio of G0/G1 phase cell decreased,the G2/M phase cell increased, the expression of following the treatment with Indirubin-3’-monoxime combined with Na, with Bcl-2 gene down-regulated,and the expression of Bax gene expression up-egulated. Conclusion Indirubin-3’-monoxime combined with Nap may obviously increase the inhibitory rate of the human esophageal cancer cell,and its mechanism may be to regulate cell cycle and to increase apoptosis-inducing effect which is regulated by several genes.

关 键 词：食管癌 靛玉红甲肟 奈达铂 细胞周期 

分 类 号：R730.53[医药卫生—肿瘤] R735.1[医药卫生—临床医学]